Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 4,168 shares of the firm's stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total transaction of $87,569.68. Following the completion of the sale, the insider now owns 100,598 shares in the company, valued at $2,113,563.98. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Crinetics Pharmaceuticals Stock Performance
NASDAQ:CRNX opened at $20.27 on Tuesday. The company has a 50-day moving average of $20.63 and a 200-day moving average of $20.13. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -6.87 and a beta of 1.20. Crinetics Pharmaceuticals, Inc. has a 52 week low of $15.91 and a 52 week high of $28.95.
Get
Crinetics Pharmaceuticals alerts:
Hedge Funds Weigh In On Crinetics Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in Crinetics Pharmaceuticals by 70.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company's stock valued at $158,000 after purchasing an additional 3,503 shares during the last quarter. Dupont Capital Management Corp lifted its holdings in Crinetics Pharmaceuticals by 36.3% during the 2nd quarter. Dupont Capital Management Corp now owns 8,629 shares of the company's stock valued at $161,000 after purchasing an additional 2,297 shares during the last quarter. Group One Trading L.P. lifted its holdings in Crinetics Pharmaceuticals by 31.6% during the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock valued at $161,000 after purchasing an additional 1,759 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Crinetics Pharmaceuticals by 17.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock valued at $164,000 after purchasing an additional 1,110 shares during the last quarter. Finally, Arizona State Retirement System bought a new position in Crinetics Pharmaceuticals during the 2nd quarter valued at about $188,000. 94.42% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, SVB Leerink raised their price target on shares of Crinetics Pharmaceuticals from $36.00 to $39.00 and gave the stock an "outperform" rating in a research report on Thursday, May 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $39.67.
Crinetics Pharmaceuticals Company Profile
(Get Rating)
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Featured Stories
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
